New Agents Committee (NAC)
Cancer Research UK's New Agents Committee (NAC) meets quarterly and is run by the Drug Development Office. It provides a one-step process for selecting new anti-cancer treatments and taking them into early clinical trials.
All submission to and meetings of the NAC are confidential.
Membership includes:
- Clinical representatives from many Key UK Clinical Centres where early/Phase I clinical trials are carried out
- Other experts in cancer drug development
- Representatives of the CDP Scientific Advisory Board (SAB)
NAC specialist preclinical and clinical expertise includes:
- drug discovery and development of small molecules and biologicals
- clinical trial design, pharmacokinetics, pharmacodynamics, functional imaging and spectroscopy
- chemistry, clinical pharmacology, radiolabelling, pharmaceutical and formulation development
- molecular biology and immunology
- toxicology
- past industry experience
For further details about the New Agents Committee, please see the Committee microsite.
